• Consensus Rating: Moderate Buy
  • Consensus Price Target: $241.60
  • Forecasted Upside: 12.15%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$215.43
▼ -1.13 (-0.52%)

This chart shows the closing price for STE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New STERIS Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STE

Analyst Price Target is $241.60
▲ +12.15% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for STERIS in the last 3 months. The average price target is $241.60, with a high forecast of $265.00 and a low forecast of $215.00. The average price target represents a 12.15% upside from the last price of $215.43.

This chart shows the closing price for STE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 investment analysts is to moderate buy stock in STERIS. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/2/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/2/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/27/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2024Piper SandlerReiterated RatingNeutral ➝ Neutral$220.00 ➝ $225.00Low
5/10/2024Needham & Company LLCReiterated RatingHoldLow
5/9/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$265.00Low
4/12/2024Needham & Company LLCReiterated RatingHoldLow
2/9/2024StephensReiterated RatingOverweight ➝ Overweight$250.00Low
2/8/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$265.00Low
2/6/2024KeyCorpInitiated CoverageOverweight$253.00Low
12/4/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$225.00 ➝ $215.00Low
11/9/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$265.00Low
10/26/2023Piper SandlerLower TargetNeutral ➝ Neutral$220.00 ➝ $215.00Low
9/25/2023StephensReiterated RatingOverweight ➝ Overweight$250.00Low
9/1/2023JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$240.00 ➝ $265.00Low
8/3/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$206.00 ➝ $225.00Low
8/3/2023KeyCorpBoost TargetOverweight ➝ Overweight$254.00 ➝ $258.00Low
8/2/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$240.00Low
7/25/2023KeyCorpBoost TargetOverweight$235.00 ➝ $254.00Low
7/17/2023StephensBoost Target$240.00 ➝ $250.00Low
5/30/2023Morgan StanleyInitiated CoverageEqual Weight$206.00Low
5/12/2023Piper SandlerBoost Target$197.00 ➝ $200.00Low
5/12/2023KeyCorpBoost Target$210.00 ➝ $235.00Low
4/14/2023Piper SandlerDowngradeOverweight ➝ Neutral$215.00 ➝ $197.00Low
2/15/2023JMP SecuritiesLower TargetMarket Outperform$250.00 ➝ $240.00Low
2/9/2023Piper SandlerLower TargetOverweight$235.00 ➝ $215.00Low
2/9/2023StephensReiterated RatingOverweight$220.00Low
11/11/2022KeyCorpLower TargetOverweight$240.00 ➝ $210.00Low
9/23/2022Needham & Company LLCDowngradeBuy ➝ HoldLow
8/4/2022JMP SecuritiesLower Target$270.00 ➝ $250.00Low
8/4/2022KeyCorpLower TargetOverweight$256.00 ➝ $240.00Low
8/4/2022Needham & Company LLCLower TargetBuy$248.00 ➝ $237.00Low
7/14/2022Piper SandlerInitiated CoverageOverweight$240.00Low
4/5/2022Wolfe ResearchInitiated CoverageOutperform$275.00Medium
2/14/2022JMP SecuritiesBoost TargetMarket Outperform$250.00 ➝ $270.00Medium
2/10/2022Needham & Company LLCBoost TargetBuy$254.00 ➝ $263.00High
11/4/2021StephensBoost TargetOverweight$255.00 ➝ $270.00Medium
11/4/2021KeyCorpBoost TargetPositive ➝ Overweight$239.00 ➝ $256.00Medium
8/11/2021KeyCorpBoost TargetPositive ➝ Overweight$227.00 ➝ $239.00Medium
8/11/2021StephensBoost TargetOverweight$217.00 ➝ $255.00Medium
8/11/2021Robert W. BairdBoost TargetOutperform$230.00 ➝ $250.00Medium
5/26/2021Needham & Company LLCUpgradeHold ➝ Buy$233.00High
5/17/2021JMP SecuritiesBoost TargetMarket Outperform$217.00 ➝ $235.00N/A
5/11/2021JMP SecuritiesBoost TargetOutperform$217.00 ➝ $235.00Medium
3/11/2021KeyCorpBoost TargetOverweight$224.00 ➝ $227.00Low
2/4/2021KeyCorpUpgradeSector Weight ➝ Overweight$224.00Low
1/20/2021Raymond JamesReiterated RatingHoldLow
1/13/2021Robert W. BairdBoost TargetOutperform$200.00 ➝ $230.00Low
11/20/2020Needham & Company LLCReiterated RatingHoldMedium
10/8/2020JMP SecuritiesBoost Target$180.00 ➝ $200.00Low
10/7/2020StephensBoost Target$170.00 ➝ $200.00Low
10/7/2020Robert W. BairdBoost TargetOutperform$175.00 ➝ $200.00Medium
10/6/2020Needham & Company LLCReiterated RatingHoldMedium
9/1/2020Robert W. BairdInitiated CoverageOutperform$175.00High
8/3/2020Needham & Company LLCInitiated CoverageHoldHigh
6/9/2020Needham & Company LLCInitiated CoverageHoldMedium
5/15/2020StephensBoost TargetOverweight$145.00 ➝ $170.00Low
3/23/2020StephensLower TargetOverweight$177.00 ➝ $145.00High
2/12/2020Northcoast ResearchReiterated RatingBuyLow
2/12/2020StephensBoost TargetOverweight$165.00 ➝ $177.00High
(Data available from 6/25/2019 forward)

News Sentiment Rating

1.34 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2023
  • 8 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/28/2023
  • 18 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/27/2024
  • 34 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/26/2024
  • 19 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/27/2024
  • 20 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/26/2024
  • 26 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
5/26/2024
  • 19 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2024

Current Sentiment

  • 19 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
STERIS logo
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.
Read More

Today's Range

Now: $215.43
Low: $214.93
High: $217.11

50 Day Range

MA: $218.73
Low: $198.94
High: $235.89

52 Week Range

Now: $215.43
Low: $195.47
High: $254.00

Volume

282,731 shs

Average Volume

494,894 shs

Market Capitalization

$21.30 billion

P/E Ratio

56.40

Dividend Yield

0.95%

Beta

0.85

Frequently Asked Questions

What sell-side analysts currently cover shares of STERIS?

The following equities research analysts have issued reports on STERIS in the last year: JMP Securities, KeyCorp, Morgan Stanley, Needham & Company LLC, Piper Sandler, Stephens, StockNews.com, and TheStreet.
View the latest analyst ratings for STE.

What is the current price target for STERIS?

5 Wall Street analysts have set twelve-month price targets for STERIS in the last year. Their average twelve-month price target is $241.60, suggesting a possible upside of 12.1%. JMP Securities has the highest price target set, predicting STE will reach $265.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $215.00 for STERIS in the next year.
View the latest price targets for STE.

What is the current consensus analyst rating for STERIS?

STERIS currently has 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for STE.

What other companies compete with STERIS?

How do I contact STERIS's investor relations team?

STERIS's physical mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The medical equipment provider's listed phone number is (440) 354-2600 and its investor relations email address is [email protected]. The official website for STERIS is www.steris.com. Learn More about contacing STERIS investor relations.